Rua Bioscience announced its official entry into the dynamic Australian medicinal cannabis market. Teaming up with Anspec, a leading pharmaceutical distribution company, Rua Bioscience product is now available to Australian patients through prescribers. In 2022, the Australian cannabis market was valued at AUD 240 million per year.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.077 NZD | +10.00% |
|
+87.80% | -35.83% |
Jul. 10 | Rua Bioscience Advances Business Strategy in Europe | MT |
May. 07 | Rua Bioscience Extends Distribution Agreement with Germany's Nimbus Health | MT |
1st Jan change | Capi. | |
---|---|---|
-35.83% | 6.8M | |
+14.19% | 5.11B | |
-33.68% | 3.43B | |
-0.74% | 3.05B | |
-24.38% | 2.59B | |
-9.94% | 2.2B | |
+39.98% | 1.86B | |
+40.95% | 1.38B | |
-14.41% | 1.37B | |
+45.87% | 1.36B |
- Stock Market
- Equities
- RUA Stock
- News Rua Bioscience Limited
- Rua Bioscience Launches First Product in Australia